Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 4/20 | 0.46 |
| ▸ | AGER | Q15109 | 3/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190556 | 1.00 | ENPP2 (0.57) | ENPP2L3MBTL1SIGMAR1PTGDR2CCR5 | |
| SCHEMBL7801189 | 0.99 | ENPP2 (0.55) | ENPP2L3MBTL1SIGMAR1PTGDR2CCR5 | |
| SCHEMBL6166891 | 0.93 | ENPP2 (0.48) | ENPP2L3MBTL1SIGMAR1PTGDR2CCR5 | |
| SCHEMBL6193454 | 0.89 | ENPP2 (0.52) | ENPP2L3MBTL1SIGMAR1PTGDR2CCR5 | |
| SCHEMBL28523905 | 0.87 | ENPP2 (0.51) | ENPP2L3MBTL1SIGMAR1PTGDR2CCR5 | |
| SCHEMBL9237582 | 0.87 | ENPP2 (0.50) | ENPP2L3MBTL1SIGMAR1PTGDR2CCR5 | |
| SCHEMBL13684267 | 0.86 | L3MBTL1 (0.63) | ENPP2L3MBTL1SIGMAR1CCR5 | |
| SCHEMBL27757526 | 0.84 | ENPP2 (0.52) | ENPP2L3MBTL1SIGMAR1PTGDR2CCR5 | |
| SCHEMBL29068551 | 0.84 | ENPP2 (0.52) | ENPP2L3MBTL1SIGMAR1PTGDR2CCR5 | |
| SCHEMBL1162705 | 0.84 | ENPP2 (0.42) | ENPP2SIGMAR1PTGDR2CCR5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234225-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-113874080-B | IL-17A modulators and uses thereof | 戴斯阿尔法公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11447468-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| CN-113874080-A | IL-17A modulators and uses thereof | 戴斯阿尔法公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3921038-A1 | IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163554-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | DICE MOLECULES SV, INC. | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | IL17A, IL2, IL15 | ENPP2 227/4885L3MBTL1 4023/4885SIGMAR1 3546/4885 |
| US-11447468-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | ENPP2 227/4885L3MBTL1 4023/4885SIGMAR1 3546/4885 |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | IL17A, IL2, IL15 | ENPP2 227/4885L3MBTL1 4023/4885SIGMAR1 3546/4885 |
| US-12234225-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | ENPP2 227/4885L3MBTL1 4023/4885SIGMAR1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.